New guidelines now recommend Type 2 diabetes patients can start with one of the newer diabetes medicine, one that can also reduce weight and protect the heart and kidney, Ariana Perez-Castells of The Wall Street Journal reports. These new guidelines could help people who are dealing with other conditions along with diabetes, such as hypertension, kidney disease, and obesity. However, the newer drugs cost more than metaformin, the typical drug received to treat type 2 diabetes, so not all patients will be able to afford these new drugs. The newer drugs include Ozempic, which is sold by Novo Nordisk (NVO), and Jardiance, which is sold by Eli Lilly (LLY). Reference Link
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on NVO:
- Novo Nordisk named ‘Catalyst Driven Idea’ at Morgan Stanley
- Novo Nordisk reports 2022 EPS DKK 24.44 vs. DKK 20.74 last year
- Deutsche Bank bearish on Roche heading into FY23, cuts to Sell
- Novo Nordisk announces FDA approval of label update for Rybelsus
- California AG files suit against drugmakers, PBMs over insulin prices